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Edited by Ned ManteiAbstract We found that prostaglandin (PG) D2, the most abun-
dant PG in the central nervous system, stimulates food intake
after intracerebroventricular administration in mice. The orexi-
genic eﬀect of PGD2 was mimicked by a selective agonist for
the DP1 receptor among two receptor subtypes for PGD2, and
abolished by its antagonist. Central administration of an antag-
onist or antisense oligodeoxynucleotide for the DP1 receptor
remarkably decreased food intake, body weight and fat mass.
Hypothalamic mRNA levels of lipocalin-type PGD synthase
were up-regulated after fasting. The orexigenic activity of
PGD2 was also abolished by an antagonist for neuropeptide Y
(NPY) Y1 receptor. Taken together, PGD2 may stimulate food
intake through central DP1 receptor coupled to the NPY system.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Central nervous system1. Introduction
PGD2 is the most abundant prostaglandin (PG) in the mam-
malian central nervous system (CNS) [1], having a variety of
central functions such as sleep induction, hypothermia and
attenuation of pain response [2–5]. PGD2 is produced from
arachidonic acid, via PGH2, by lipocalin-type PGD synthase
(L-PGDS), which is localized in the arachnoid membrane
and choroid plexus of the brain [6]. PGD2 and PGE2 are posi-
tional isomers produced from the same precursor PGH2, and
sometimes exhibit opposing biological activities in the CNS
[2]. For example, PGD2 induces sleep while PGE2 promotesAbbreviations: PG, prostaglandin; CNS, central nervous system; L-
PGDS, lipocalin-type prostaglandin D synthase; ODN, oligodeoxy-
nucleotide; NPY, neuropeptide Y; i.c.v., intracerebroventricular;
DMSO, dimethylsulfoxide; ACSF, artiﬁcial cerebrospinal ﬂuid;
COX, cyclooxygenase; mPGES, microsomal prostaglandin E2 syn-
thase
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doi:10.1016/j.febslet.2008.01.050wakefulness [2–4], and whereas PGD2 lowers body tempera-
ture, PGE2 elevates it after central administration [7].
Recently, we found that centrally administered PGE2 sup-
pressed food intake via the EP4 receptor among four receptor
subtypes for PGE2 [8]; however, the role of PGD2 in regulating
food intake is unknown.
In the current study, we found that centrally administered
PGD2 stimulated food intake in mice. Two receptor subtypes
having aﬃnity for PGD2 are known: the DP1 receptor [9,10]
and the DP2 receptor originally termed as the chemoattractant
receptor-homologous molecule expressed on T-helper type 2
cells [11,12]. Both subtypes are G-protein coupled receptors
and are present in the CNS. We examined which subtype med-
iated the orexigenic eﬀect of PGD2 by using a DP1 or DP2
receptor-selective agonist. Furthermore, to investigate the
involvement of endogenous PGD2 on food intake regulation,
we used an antagonist or an antisense oligodeoxynucleotide
(ODN) for the DP1 receptor. We also found that L-PGDS-like
immunoreactivity was localized in the hypothalamus, which is
important for regulating food intake, and hypothalamic
mRNA levels of L-PGDS were increased after fasting.
Neuropeptide Y (NPY), the most potent orexigenic peptide
in the hypothalamus, mediates the orexigenic actions of vari-
ous endogenous peptides [13–15]. We also tested whether the
orexigenic eﬀect of PGD2 is coupled to the NPY system down-
stream of the DP1 receptor.
2. Materials and methods
2.1. Materials
PGD2 was obtained from Nacalai Tesque Inc. (Kyoto, Japan), and
the DP1 receptor agonist BW245C, the DP1 receptor antagonist
BWA868C and the DP2 receptor agonist 13,14-dihydro-15-keto-
PGD2 were purchased from Cayman Chemical (Ann Arbor, MI) [9–
12]. NPY Y1 receptor antagonist BIBO3304 was generously supplied
by Boehringer-Ingelheim Pharma (Rheinland Pfalz, Germany).
2.2. Cannula implantation
Male ddY mice [8,16–24] at 7 weeks of age were obtained from
Japan SLC (Shizuoka, Japan). Each mouse was individually housed
under regulated conditions (22–24 C on a 12 h light–dark cycle with
light on at 7 a.m.). Each mouse had free access to food pellet and
water unless otherwise indicated. All experiments were approved by
Kyoto University Ethics Committee for Animal Research Use.
Intracerebroventricular (i.c.v.) injection was performed as describedblished by Elsevier B.V. All rights reserved.
680 K. Ohinata et al. / FEBS Letters 582 (2008) 679–684previously [8,16–19,23]. Brieﬂy, mice were anesthetized with sodium
pentobarbital (80–85 mg/kg i.p.) and placed in a stereotaxic instru-
ment. A 24-gauge cannula beveled at one end over a distance of
3 mm (Safelet-Cas, Nipro, Osaka, Japan) was implanted at a position
of 0.9 mm posterior to the bregma and 0.9 mm lateral to the suture
into the third cerebral ventricle. Animals were tested 1 week or more
after implantation.
2.3. Food intake experiment
Each drug was dissolved in dimethylsulfoxide (DMSO) and the solu-
tion was diluted 20 times by artiﬁcial cerebrospinal ﬂuid (ACSF;
138.9 mM NaCl, 3.4 mM KCl, 1.3 mM CaCl2, 4.0 mM NaHCO3,
0.6 mM NaH2PO4, 5.6 mM glucose, pH 7.4). The test started at
2 p.m. All drugs were i.c.v. injected with 4 ll 5% DMSO ACSF or
vehicle alone in sated conscious mice without food deprivation.
PGD2 (0.6 or 6 nmol/mouse) in 4 ll 5% DMSO ACSF or vehicle alone
was i.c.v injected in non-fasted mice (n = 12–16). A DP1 receptor-selec-
tive agonist BW245C (5 nmol/mouse) or a DP2 receptor-selective ago-
nist 13,14-dihydro-15-keto-PGD2 (6 nmol/mouse) was centrally
administrated (n = 7–14). PGD2 (0.6 nmol/mouse) and the selective
DP1 receptor antagonist BWA868C (1.6 nmol/mouse) in 4 ll vehicle
were coadministered (n = 6–7). A combination of PGD2 (6 nmol/
mouse) and the NPY Y1 receptor antagonist BIBO3304 (5 nmol/
mouse) in 4 ll vehicle was i.c.v. coadministered (n = 6–7). The DP1
receptor antagonist BWA868C alone (1.6 or 16 nmol/mouse) was also
injected (n = 11–13). The weight of the food pellets in each cage was
measured 0, 60 and 120 min after i.c.v. injection and the cumulative
food intake was calculated. After the experiment, cannula placement
was conﬁrmed by i.c.v. administration of dye.
2.4. Antisense oligodeoxynucleotide study
The sequence of the phosphorothioate antisense oligodeoxynucleo-
tide (ODN) is based on the transcription initiation site of the mouse
DP1 receptor gene [7] (GenBank Accession Number NM008962).
The DP1 receptor-antisense ODN (5
0-CAGCGATAGGACTCGTT-
CAT-3 0) and scrambled ODN (5 0-GCTCAGGATAGCGACTACTT-
3 0) were synthesized by Hokkaido System Science Co., Ltd.
(Hokkaido, Japan). We found no homology between the DP1 recep-
tor-antisense sequence and other known cDNAs in the GenBank data-
base. The DP1 receptor-antisense or scrambled ODN in 4 ll ACSF was
i.c.v. injected every 24 h on day 0–2 (n = 10). One day after the third
injection of the DP1 receptor-antisense ODN, 2 lg of PGD2 was
i.c.v. injected and food intake was measured. On day 3, the mice were
sacriﬁced and their epididymal fat weight was measured (n = 3).
2.5. RNA preparation from hypothalamus and quantitative RT-PCR
Each mouse hypothalamus was cut after decapitation under deep
anesthesia, and kept in RNA later RNA Stabilization Reagent (QIA-
GEN Sciences Inc., Germantown, MD) until RNA extraction. Total
RNA was extracted from the hypothalamus using the RNeasy Lipid
Tissue Kit (QIAGEN Sciences Inc.), and transcribed to cDNA with
random primers and oligo-dT by Superscript III reverse transcriptase
(Invitrogen Corp., Carlsbad, CA). For quantitative PCR, we ampliﬁed
the cDNA using Applied Biosystems Prism 7000 Sequence Detection
System (Foster City, CA) with Platinum SYBER Green qPCR Super-
Mix-UDG with ROX solution (Invitrogen Corp.) and each primer set
speciﬁc for mouse b-actin, cyclooxygenase (COX)-1, COX-2, L-PGDS,
microsomal PGE synthase (mPGES), and EP4 receptor according to
the manufacturers instructions (Table 1). The reactions were cycled
40 times with denaturation at 95 C for 15 s, and with annealing and
elongation at 60 C for 30 s. In case of DP1 receptor, quantitativeTable 1







EP4 receptor GATGGCAGAAGCTACGCTATTGRT-PCR was performed with annealing and elongation at 57 and
72 C for 30 s using the same primer as described previously [25].
The relative expression level of each mRNA was normalized using
the mRNA level of b-actin, which was not aﬀected by fasting (data
not shown).
2.6. Immunohistochemistry
Under deep anesthesia with ether, the mice were intracardially per-
fused with phosphate-buﬀered saline (pH 7.4), followed by 0.25% para-
formaldehyde in 0.1 M sodium phosphate (pH 7.3). The brains were
then removed, cryoprotected, and frozen. Serial 20-lm-thick sections
of frozen coronal slices were incubated with the anti-L-PGDS [2],
anti-DP1 receptor [25] or anti-NPY [27] antibody, followed with each
biotinylated second antibody. Immunoreactivity was visualized using
the avidin–biotin peroxidase complex method and diaminobenzidine
reaction. Non-speciﬁc binding without each antibody for L-PGDS,
DP1 receptor and NPY was not observed (data not shown).
2.7. Statistical analysis
Results are expressed as the means ± S.E.M. When comparing two
groups or more, unpaired Students t-test or analysis of variance (AN-
OVA) followed by Fishers test, respectively, was used to assess diﬀer-
ences among groups. P-values less than 0.05 were considered
signiﬁcant.3. Results
3.1. Centrally administered PGD2 stimulates food intake
through the DP1 receptor
PGD2 at a dose of 0.6 and 6 nmol/mouse stimulated food in-
take in a dose-dependent manner 60 min after central adminis-
tration in non-fasted mice (Fig. 1A). A DP1 receptor-selective
agonist, BWA245C, stimulated food intake at a dose of
5 nmol/mouse after i.c.v. administration to the same level as
that with PGD2 (Fig. 1B); however, a selective DP2 agonist
13,14-dihydro-15-keto-PGD2 did not change food intake at a
dose of 6 nmol/mouse (Fig. 1B). The orexigenic eﬀect of
PGD2 was completely blocked by the selective DP1 receptor
antagonist BWA868C (Fig. 1C). The orexigenic activity of
PGD2 was also completely abolished by pretreatment with
antisense ODN for the DP1 receptor (Fig. 1D). In contrast,
the orexigenic activity of PGD2 was not impaired in mice pre-
treated with scrambled ODN (Fig. 1D). These results suggest
that exogenous PGD2-induced feeding is mediated by the
DP1 receptor.3.2. Involvement of endogenous PGD2 and DP1 receptor in food
intake regulation
To investigate the role of endogenous PGD2 in food intake
regulation, we tested the eﬀects of i.c.v. administration of the
DP1 receptor antagonist or the DP1 receptor-antisense ODN
on food intake, body weight and fat mass. Bolus i.c.v. injection
















































































Fig. 1. Eﬀect of i.c.v. administration of PGD2 on food intake. (A)
Central administration of PGD2 (0.6 and 6 nmol/mouse) stimulated
the food intake of non-fasted conscious mice (n = 12–16). (B) The
selective DP1 receptor agonist BW245C (5 nmol/mouse) but not DP2
agonist 13,14-dihydro-15-keto-PGD2 (DKPGD2; 6 nmol/mouse) stim-
ulated food intake (n = 7–14). (C) The orexigenic activity of i.c.v.
injected PGD2 (0.6 nmol/mouse) was blocked by the selective DP1
receptor antagonist BWA868C (1.6 nmol/mouse) in non-fasted mice
(n = 6–7). (D) DP-antisense ODN pretreatment for 3 days (1 nmol/
mouse/day) inhibited the orexigenic activity of PGD2 at a dose of
6 nmol/mouse. Each column represents the means ± S.E.M. *P < 0.05,
**P < 0.01 compared with the ACSF-treated control group by
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Fig. 2. Involvement of endogenous PGD2 and the DP1 receptor on
food intake regulation in the CNS. (A) I.c.v. injection of the DP1
receptor antagonist BWA868C (1.6 and 16 nmol/mouse) decreased
food intake in non-fasted mice (n = 11–13). (B–D) Mice were injected
with the DP1 receptor-antisense (0.3 and 1 nmol/mouse/day) or
scrambled ODN every 24 h for 3 days. The DP1 receptor-antisense
ODN decreased daily food intake (B), body weight (C) n = 10, and
epididymal fat weight on day 3 (D). Results are expressed as the
mean ± S.E.M. *P < 0.05, **P < 0.01 compared with the ACSF-treated
control group by ANOVA followed by Fishers test or unpaired
Students t-test.
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fasted mice (Fig. 2A), suggesting that the DP1 receptor may
be activated by endogenous PGD2 under normal conditions.
Administration of antisense ODN for the DP1 receptor (0.3
and 1 nmol/mouse/day for 3 days) also markedly suppressed
the daily food intake of mice in a dose-dependent manner even
after the ﬁrst injection (Fig. 2B). The decrease in daily food in-
take recovered to the normal level 2 or 4 days after the ﬁnal
treatment of antisense ODN for the DP1 receptor at a dose
of 0.3 or 1 nmol/mouse/day, respectively, suggesting that the
suppression of food intake was not induced by the irreversible
toxicity of ODN. A remarkable decrease in body weight was
also observed after the administration of antisense ODN for
the DP1 receptor (Fig. 2C). On day 3, antisense-treated mice
showed a 70% decrease in daily food intake and a 20% de-
crease in body weight compared to mice treated with scram-
bled ODN (Fig. 2B and C). The epididymal fat mass of mice
treated with antisense ODN for the DP1 receptor on day 3 also
decreased by 50% (Fig. 2D). Taken together, DP1 receptor
stimulation with endogenous PGD2 may drive the orexigenic
system in the CNS that regulates food intake, body weight
and fat deposition.
3.3. Hypothalamic mRNA levels of L-PGDS are increased after
fasting
It was reported that L-PGDS, which synthesizes PGD2 from
PGH2 in the brain, is localized in the leptomeninges and cho-roid plexus [6,25]. We also investigated the localization of
L-PGDS in the hypothalamus, which is an important site for
food intake regulation in the CNS. We found that L-PGDS-
like immunoreactivity was present in ependymal cells facing
the third ventricle and oligodendroglial cells of the median
eminence of the hypothalamus (Fig. 3). These suggest that
L-PGDS is present in the hypothalamus as well as the leptome-
ninges and choroid plexus.
To test whether hypothalamic L-PGDS was activated in re-
sponse to energy status, we measured its mRNA levels using
the quantitative RT-PCR during starvation. Hypothalamic
mRNA levels of L-PGDS were signiﬁcantly increased after
fasting for 48 h (Fig. 4A). However, the mRNA levels of
DP1 receptor, mPGES, EP4 receptor, COX-1 and COX-2 did
not change (Fig. 4). Taken together, L-PGDS gene expression
may be up-regulated in response to starvation, similarly to
hypothalamic orexigenic NPY, which is activated during peri-
ods of negative energy balance [14].
3.4. The orexigenic activity of PGD2 is coupled to the NPY-Y1
receptor system
The selective NPY Y1 antagonist BIBO3304 at a dose of
5 nmol/mouse [16,23] completely blocked the orexigenic activ-
ity of PGD2 (Fig. 5), which suggests that PGD2 stimulates
food intake via Y1 receptor downstream of the DP1 receptor.
We also examined the localization of the DP1 receptor and
NPY in the hypothalamus. It has been reported that mRNA
expression and protein levels of DP1 receptor in brain paren-
chyma are considerably lower than in the arachnoid membrane
Fig. 3. Localization of L-PGDS in the hypothalamus of the mouse
brain. L-PGDS-like immunoactivity was observed in ependymal cells
facing the third ventricle and oligodendroglial cells of the median
eminence (ME). Inset is a higher magniﬁcation of the view of the ME.




















































































F.   COX-2E.   COX-1 
Fig. 4. Hypothalamic mRNA levels of L-PGDS, DP1 receptor,
mPGES, EP4 receptor COX-1 and COX-2 after fasting. The hypo-
thalamus was obtained from mice deprived food pellets for 48 h with
free access to water, and their mRNA levels of (A) L-PGDS, (B) DP1
receptor, (C) mPGES, (D) EP4 receptor (E) COX-1 and (F) COX-2
were measured by quantitative PCR. Relative expressions normalized
by that of non-food-deprived mice were indicated. Values are
presented as the mean ± S.E.M. (n = 11). *P < 0.05, compared with

















Fig. 5. The orexigenic eﬀect of PGD2 (6 nmol/mouse) was blocked by
the NPY Y1 receptor antagonist BIBO3304 (5 nmol/mouse) in non-
fasted mice (n = 6–7). *P < 0.05 compared with the ACSF-treated
control group by ANOVA followed by Fishers test.
Fig. 6. Localization of DP1 receptor and NPY in the hypothalamus of
the mouse brain. (A) DP1 receptor-like immunoactivity was localized
in the median eminence (ME) of the hypothalamus (arrows). (B) NPY-
like immunoreactivity was localized not only in the arcuate nucleus
(Arc) but also in the ME. NPY-positive neurons were indicated by
arrows (inset). Coronal sections 2.18–2.30 mm caudal to the bregma.
Insets are higher magniﬁcation views of the boxed areas. Scale bars:
50 lm; insets, 25 lm.
682 K. Ohinata et al. / FEBS Letters 582 (2008) 679–684in the basal forebrain [26]. Indeed, DP1 receptor-like immuno-
reactivity was quite low; however, its immunoreactivity was
observed in the median eminence of the hypothalamus
K. Ohinata et al. / FEBS Letters 582 (2008) 679–684 683(Fig. 6A). Non-speciﬁc binding was not observed in the ab-
sence of the DP1 receptor-antibody (data not shown). NPY-
positive neurons are present in large number of cells in the
arcuate nucleus (Fig. 6B, upper inset), and this is consistent
with previous reports [13–15]. NPY-like immunoreactivity
was also present in the median eminence (Fig. 6B, lower inset).
DP1 receptor-possessing neurons in the median eminence
probably directly or indirectly innervate NPY neurons in the
regulation of food intake. Taken together, we hypothesize that
PGD2 produced by L-PGDS in the median eminence might
stimulate food intake via neurons possessing DP1 receptor
and NPY in the hypothalamus.4. Discussion
We found that centrally administered PGD2 stimulates food
intake through the DP1 receptor. Blockade of the DP1 receptor
using a selective antagonist or antisense ODN decreased food
intake, suggesting that the central orexigenic system under nor-
mal physiological conditions may be maintained by activation
of the DP1 receptor with endogenous PGD2. Repeated admin-
istration of antisense oligonucleotide for the DP1 receptor de-
creased body weight and fat deposition as well as food intake.
We also found that L-PGDS was localized in the hypothala-
mus of the mouse brain, and its mRNA levels were up-regu-
lated after fasting.
Among ﬁve receptor subtypes for NPY, the Y1 receptor is
known predominantly to mediate orexigenic activity [13–
15,28–30]. PGD2-induced orexigenic action was completely
blocked by the Y1 antagonist, suggesting that PGD2 stimulates
food intake via the DP1 receptor followed by activating the Y1
receptor. We thus examined whether the DP1 receptor was
present in the hypothalamus, where NPY are abundantly
localized [11–13]. The DP1 receptor as well as NPY was also
observed in the hypothalamus of the mouse brain. These re-
sults do not contradict our pharmacological data on PGD2
and DP1 receptors for food intake. It is known that the hypo-
thalamus receives peripheral humoral input in response to the
energy condition. Further investigations will assess the physio-
logical signiﬁcance of the hypothalamic PGD2–DP1 receptor
system in the regulation of food intake.
PGE2, a positional isomer of PGD2, suppresses food intake
after central administration at a dose of 0.1 nmol/mouse [8,31].
Among four receptor subtypes, an EP4 selective agonist de-
creased food intake, and PGE2 or EP4 agonist-induced anorex-
igenic activity was blocked by EP4 antagonist, suggesting that
the suppression of food intake by PGE2 is mediated by EP4
receptor [8]. In addition, central administration of PGD2 in-
duces sleep [2–4]. Recently, it was reported that the EP4 recep-
tor mediates the wakefulness induced by PGE2 [32]. It is
noteworthy that PGE2 and PGD2 have opposite eﬀects on
food intake regulation as well as sleep via activation of the
EP4 and DP1 receptors, respectively.
Sleep deprivation is known to stimulate food intake [33]. It
has been hypothesized that sleep-promoting and orexigenic
substances might be increased after sleep deprivation. PGD2
in the CNS induces sleep through the DP1 receptor in the lep-
tomeninges of the basal forebrain [2–4,26,34]. Lack of sleep
leads to increase PGD2 concentration in the CSF of rats
[35]. In the current study, we revealed that central PGD2 stim-ulated food intake via DP1 receptor. Taken together, the
PGD2 system might be associated with hyperphasia after sleep
deprivation.
In conclusion, we found that PGD2 in the CNS stimulates
food intake through the DP1 receptor, and blockade of the
DP1 receptor by a selective antagonist or antisense ODN de-
creases food intake. Our results suggest that endogenous
PGD2 may play an important role in food intake regulation
under normal physiological conditions.
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